Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4

Oncogene

Volumn 36, Issue 7, 2017, Pages 912-921

  Harjes, U ^a,g,h   Bridges, E ^a   Gharpure, K M ^b   Roxanis, I ^a   Sheldon, H ^a   Miranda, F ^c   Mangala, L S ^b,d   Pradeep, S ^b   Lopez Berestein, G ^d,e   Ahmed, A ^c   Fielding, B ^f   Sood, A K ^b,d,e   Harris, A L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f UNIVERSITY OF SURREY   (United Kingdom)

^g UNIVERSITY OF LEUVEN   (Belgium)

^h DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ETOMOXIR; FATTY ACID BINDING PROTEIN 4; NOTCH1 RECEPTOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SMALL INTERFERING RNA; SUCCINATE DEHYDROGENASE (UBIQUINONE); VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; NOTCH1 PROTEIN, HUMAN; TUMOR MARKER; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GROWTH; CAPILLARY DENSITY; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; LIPOGENESIS; METASTASIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CANCER GRADING; CELL MOTION; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; DRUG SCREENING; FOLLOW UP; GENETICS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; FATTY ACID-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84984620729     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.256     Document Type: Article

References (32)

1. Schoors S, Bruning U, Missiaen R, Queiroz KC, Borgers G, Elia I et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 2015; 520: 192-197.
2. Mashek DG, Coleman RA. Cellular fatty acid uptake: the contribution of metabolism. Curr Opin Lipidol 2006; 17: 274-278.
3. Bao Z, Malki MI, Forootan SS, Adamson J, Forootan FS, Chen D et al. A novel cutaneous fatty acid-binding protein-related signaling pathway leading to malignant progression in prostate cancer cells. Genes Cancer 2013; 4: 297-314.
4. Levi L, Wang Z, Doud MK, Hazen SL, Noy N. Saturated fatty acids regulate retinoic acid signalling and suppress tumorigenesis by targeting fatty acid-binding protein 5. Nat Commun 2015; 6: 8794.
5. Harjes U, Kalucka J, Carmeliet P. Targeting fatty acid metabolism in cancer and endothelial cells. Crit Rev Oncol Hematol 2015; 97: 15-21.
6. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-1945.
7. Smith AJ, Thompson BR, Sanders MA, Bernlohr DA. Interaction of the adipocyte fatty acid-binding protein with the hormone-sensitive lipase: regulation by fatty acids and phosphorylation. J Biol Chem 2007; 282: 32424-32432.
8. Coe NR, Simpson MA, Bernlohr DA. Targeted disruption of the adipocyte lipidbinding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 1999; 40: 967-972.
9. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab 2013; 18: 153-161.
10. Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM et al. Fatty acid uptake and lipid storage induced by HIF-1alpha contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep 2014; 9: 349-365.
11. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 17: 1498-1503.
12. Wang H, Huang X, Zhang J, Shao N, Chen LO, Ma D et al. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. Clin Chim Acta 2014; 436: 243-248.
13. Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL et al. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res 2011; 71: 6030-6039.
14. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 2011; 71: 6073-6083.
15. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007; 67: 1757-1768.
16. Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY et al. Dll4 inhibition plus Aflibercept markedly reduces ovarian tumor growth. Mol Cancer Ther 2016; 15: 1344-1352.
17. Harjes U, Bridges E, McIntyre A, Fielding BA, Harris AL. Fatty acid-binding protein 4, a point of convergence for angiogenic and metabolic signaling pathways in endothelial cells. J Biol Chem 2014; 289: 23168-23176.
18. Pike LS, Smift AL, Croteau NJ, Ferrick DA, Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta 2011; 1807: 726-734.
19. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010; 18: 185-197.
20. Masiero M, Simoes FC, Han HD, Snell C, Peterkin T, Bridges E et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 2013; 24: 229-241.
21. Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 2011; 12: 551-564.
22. Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng M, Ince TA et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 2009; 23: 3865-3873.
23. Garin-Shkolnik T, Rudich A, Hotamisligil GS, Rubinstein M. FABP4 attenuates PPARgamma and adipogenesis and is inversely correlated with PPARgamma in adipose tissues. Diabetes 2014; 63: 900-911.
24. Rosca MG, Vazquez EJ, Chen Q, Kerner J, Kern TS, Hoppel CL. Oxidation of fatty acids is the source of increased mitochondrial reactive oxygen species production in kidney cortical tubules in early diabetes. Diabetes 2012; 61: 2074-2083.
25. Huttemann M, Lee I, Pecinova A, Pecina P, Przyklenk K, Doan JW. Regulation of oxidative phosphorylation, the mitochondrial membrane potential, and their role in human disease. J Bioenerg Biomembr 2008; 40: 445-456.
26. Cataltepe O, Arikan MC, Ghelfi E, Karaaslan C, Ozsurekci Y, Dresser K et al. Fatty acid binding protein 4 is expressed in distinct endothelial and non-endothelial cell populations in glioblastoma. Neuropathol Appl Neurobiol 2012; 38: 400-410.
27. Olsauskas-Kuprys R, Zlobin A, Osipo C. Gamma secretase inhibitors of Notch signaling. Onco Targets Ther 2013; 6: 943-955.
28. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015; 16: 928-936.
29. Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X et al. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin Cancer Res 2013; 19: 6943-6956.
30. Brandes RP, Weissmann N, Schroder K. Nox family NADPH oxidases: molecular mechanisms of activation. Free Radic Biol Med 2014; 76: 208-226.
31. Schultheis B, Strumberg D, Santel A, Vank C, Gebhardt F, Keil O et al. First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol 2014; 32: 4141-4148.
32. Wu J. Statistical inference for tumor growth inhibition T/C ratio. J Biopharm Stat 2010; 20: 954-964.